These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33459227)

  • 1. Impact of Pharmacogenetic Determinants of Tacrolimus and Mycophenolate on Adverse Events in Renal Transplant Patients.
    Thishya K; Sreenu B; Raju SB; Kutala VK
    Curr Drug Metab; 2021; 22(5):342-352. PubMed ID: 33459227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients.
    Genvigir FDV; Nishikawa AM; Felipe CR; Tedesco-Silva H; Oliveira N; Salazar ABC; Medina-Pestana JO; Doi SQ; Hirata MH; Hirata RDC
    Pharmacotherapy; 2017 May; 37(5):535-545. PubMed ID: 28316087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
    Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
    Miura M; Kagaya H; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
    Ther Drug Monit; 2008 Oct; 30(5):559-64. PubMed ID: 18695635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients.
    Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Biondi F; Sanguedolce R; Vizzini G; Palazzo U; Polidori P; Triolo F; Gridelli B; D'Alessandro N
    Ann Transplant; 2009; 14(1):23-31. PubMed ID: 19289993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
    Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Vizzini G; Salis P; Caccamo C; Bertani T; Palazzo U; Polidori P; Gridelli B; D'Alessandro N
    Int J Mol Med; 2011 Dec; 28(6):1093-102. PubMed ID: 21922127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
    Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
    Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.
    Zhang X; Wang Z; Fan J; Liu G; Peng Z
    Eur J Clin Pharmacol; 2011 Aug; 67(8):803-13. PubMed ID: 21359536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
    Yildirim E; Şahin G; Kaltuş Z; Çolak E
    Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.
    Elens L; Capron A; Kerckhove VV; Lerut J; Mourad M; Lison D; Wallemacq P; Haufroid V
    Pharmacogenet Genomics; 2007 Oct; 17(10):873-83. PubMed ID: 17885626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients.
    Gómez-Bravo MA; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Alamo JM; Millán O; Brunet M
    J Clin Pharmacol; 2013 Nov; 53(11):1146-54. PubMed ID: 23900887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.
    Sy SK; Heuberger J; Shilbayeh S; Conrado DJ; Derendorf H
    AAPS J; 2013 Oct; 15(4):1189-99. PubMed ID: 23990505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.
    de Wildt SN; van Schaik RH; Soldin OP; Soldin SJ; Brojeni PY; van der Heiden IP; Parshuram C; Nulman I; Koren G
    Eur J Clin Pharmacol; 2011 Dec; 67(12):1231-41. PubMed ID: 21698374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Pharmacogenet Genomics; 2019 Jan; 29(1):9-17. PubMed ID: 30489455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.